Seung-Young Oh1,2, Jeong-Hwan Lee1, Hyuk-Joon Lee3,4, Tae Han Kim1,5, Yeon-Ju Huh1,6, Hye-Seong Ahn7, Yun-Suhk Suh1, Seong-Ho Kong1, Ga Hee Kim8,9, Su Joa Ahn10, Se Hyung Kim10, Yunhee Choi11, Han-Kwang Yang1,12. 1. Department of Surgery, Seoul National University College of Medicine, Seoul, Korea. 2. Critical Care Center, Seoul National University Hospital, Seoul, Korea. 3. Department of Surgery, Seoul National University College of Medicine, Seoul, Korea. appe98@snu.ac.kr. 4. Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea. appe98@snu.ac.kr. 5. Department of Surgery, Gyeongsang National University College of Medicine, Gyeongsang National University Changwon Hospital, Changwon, Korea. 6. Departmemt of Surgery, Ewha Womans University Mokdong Hospital, Seoul, Korea. 7. Department of Surgery, Seoul National University Boramae Medical Center, Seoul, Korea. 8. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. 9. Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Asan Digestive Disease Research Institute, Seoul, Korea. 10. Department of Radiology, Seoul National University College of Medicine, Seoul, Korea. 11. Medical Research Collaborating Center, Seoul National University College of Medicine, Seoul, Korea. 12. Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
Abstract
BACKGROUND: Understanding the natural progression of untreated gastric cancer is critical for determining the disease prognosis as well as treatment options and timing. The aim of this study is to analyze the natural history of gastric cancer. PATIENTS AND METHODS: We included patients with gastric cancer who had not received any treatment and were staged using endoscopy/endoscopic ultrasonography and computed tomography on at least two follow-up visits during intervals of nontreatment. Tumor volumes were also measured in addition to the staging. Survival of each stage at diagnosis was also analyzed. RESULTS: A total of 101 patients were included. The mean follow-up period was 35.1 ± 34.4 months. The gastric cancer doubling time was 11.8 months for T1 and 6.2 months for T4. The progression time from early gastric cancer to advanced gastric cancer was 34 months. It decreased as the stages advanced: from 34 months between tumor-nodes-metastasis stage I and II to 1.8 months between stage III and IV. No variable was identified as a risk factor for cancer progression. The 5-year survival rates of untreated patients were 46.2% in stage I and 0% in stage II, stage III, and stage IV. CONCLUSIONS: The progression and doubling times of gastric cancer shorten as the stages advance. Objective data reported in this study can be a critical factor in determining treatment timing and screening interval.
BACKGROUND: Understanding the natural progression of untreated gastric cancer is critical for determining the disease prognosis as well as treatment options and timing. The aim of this study is to analyze the natural history of gastric cancer. PATIENTS AND METHODS: We included patients with gastric cancer who had not received any treatment and were staged using endoscopy/endoscopic ultrasonography and computed tomography on at least two follow-up visits during intervals of nontreatment. Tumor volumes were also measured in addition to the staging. Survival of each stage at diagnosis was also analyzed. RESULTS: A total of 101 patients were included. The mean follow-up period was 35.1 ± 34.4 months. The gastric cancer doubling time was 11.8 months for T1 and 6.2 months for T4. The progression time from early gastric cancer to advanced gastric cancer was 34 months. It decreased as the stages advanced: from 34 months between tumor-nodes-metastasis stage I and II to 1.8 months between stage III and IV. No variable was identified as a risk factor for cancer progression. The 5-year survival rates of untreated patients were 46.2% in stage I and 0% in stage II, stage III, and stage IV. CONCLUSIONS: The progression and doubling times of gastric cancer shorten as the stages advance. Objective data reported in this study can be a critical factor in determining treatment timing and screening interval.
Authors: Thomas K L Lui; Kathy Leung; Chuan-Guo Guo; Vivien W M Tsui; Joseph T Wu; Wai K Leung Journal: Gastroenterology Date: 2020-05-17 Impact factor: 22.682
Authors: Sarah N Fuller; Ahmad Shafiei; David J Venzon; David J Liewehr; Michal Mauda Havanuk; Maran G Ilanchezhian; Maureen Edgerly; Victoria L Anderson; Elliot B Levy; Choung D Hoang; Elizabeth C Jones; Karlyne M Reilly; Brigitte C Widemann; Bradford J Wood; Hadi Bagheri; Jaydira Del Rivero Journal: Curr Oncol Date: 2021-11-01 Impact factor: 3.677
Authors: J-J Tuech; A Gangloff; F Di Fiore; P Michel; C Brigand; K Slim; M Pocard; L Schwarz Journal: J Visc Surg Date: 2020-03-31 Impact factor: 2.043